ArticleMedical science monitor : international medical journal of experimental and clinical research2012
The role of Interleukin-17A and Interleukin-17E in multiple myeloma patients.
Article in Medical science monitor : international medical journal of experimental and clinical research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 28 citations in OpenAlex.
- Assessment of Blocking Interleukin-17 Antibodies in Tumor Immunotherapy with Checkpoint Inhibitors or Tumor-Specific T Cells in Implanted and UVB-Induced Cancers.Biomedicines · 2026Article
- The IL-17 family in diseases: from bench to bedside.Signal transduction and targeted therapy · 2023Review
- Evaluation of Cell-Specific Epigenetic Age Acceleration in People With Multiple Sclerosis.Neurology · 2023Article
- New insights into the function of Interleukin-25 in disease pathogenesis.Biomarker research · 2023Review
- High serum IL-17A is associated with bone destruction in newly diagnosed multiple myeloma patients.Frontiers in oncology · 2022Article
- Interleukin-25: New perspective and state-of-the-art in cancer prognosis and treatment approaches.Cancer medicine · 2021Review
- Predictive Role of Immune Profiling for Survival of Multiple Myeloma Patients.Frontiers in immunology · 2021Review
- Autophagy impacts on oxaliplatin-induced hepatocarcinoma apoptosis via the IL-17/IL-17R-JAK2/STAT3 signaling pathway.Oncology letters · 2017Article
- The Low Expression of IL-37 Involved in Multiple Myeloma - Associated Angiogenesis.Medical science monitor : international medical journal of experimental and clinical research · 2016Article
- Targeting IL-17A in multiple myeloma: a potential novel therapeutic approach in myeloma.Leukemia · 2016Article
- Elevated Th22 as well as Th17 cells associated with therapeutic outcome and clinical stage are potential targets in patients with multiple myeloma.Oncotarget · 2015Article
- Clinical features and expressions of Foxp3 and IL-17 in type 1 autoimmune pancreatitis in China.Medical science monitor : international medical journal of experimental and clinical research · 2014Article
- Recent advances in antimultiple myeloma drug development.Pharmaceutical patent analyst · 2014Review
- Beta2-microglobulin as a diagnostic marker in cerebrospinal fluid: a follow-up study.Disease markers · 2014Article
- The role of interleukin 17 in tumour proliferation, angiogenesis, and metastasis.Mediators of inflammation · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTumor growth in multiple myeloma (MM) is regulated by the cytokine networks which are produced by myeloma cells and the microenvironment of the bone marrow. Interleukin-17 (IL-17) is implicated in the increased angiogenesis in the bone marrow of MM. Recent studies reported elevated levels of interleukin 17A (IL-17A) in the sera of patients with advanced stages according to Durie-Salmon classification. MATERIAL/
methodsWe compared the concentration of IL-17A and IL-17E in the blood serum of 34 newly diagnosed MM patients with healthy subjects' sera. We also evaluated the concentration of IL-17A and IL-17E in the blood serum of MM patients and the relation to the percentage of plasma cells and other clinical parameters. The concentration of IL-17E and IL-17A of healthy subjects and patients with MM was assessed by enzyme-linked immunosorbent assay (ELISA).
resultsOur data confirm that IL-17A and IL-17E serum levels were significantly higher in all MM patients and also in patients with advanced stage compared with healthy subjects. We found the correlation between serum levels of IL-17A in MM patients and percentage of plasma cells. Our results also showed that if serum levels of IL-17E were higher in MM patients, the percentage of plasma cells and beta-2-microglobulin levels were lower.
conclusionsThe IL-17 family of cytokines may suppress or promote tumor growth. There seems to be some balance between the effects of IL-17A and IL-17E. The role of increased levels of IL-17E needs further investigation to understand its role in the pathobiology of MM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.